---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-060156"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:44:52.816028+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Oruka Therapeutics fixes purchase price error, adds employee warrants in merger with ARCA

## Summary
- July 3, 2024: Oruka and parties signed Letter Agreement correcting a scrivener's error in the Purchase Price definition.
- Same day: Oruka entered an Amended and Restated Subscription Agreement adding warrants for certain employees and service providers.
- Both actions relate to the pending merger with ARCA biopharma (ABIO) under the April 3, 2024 Merger Agreement.
- No changes to the $275M aggregate subscription amount or other key deal terms; corrections are procedural.

## SEC filing metadata
- accession: 0001213900-24-060156
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390024060156/0001213900-24-060156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea0209134-8k425_arcabio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-060156
- JSON: https://secwatch.observer/filing/0001213900-24-060156.json
- Plain text: https://secwatch.observer/filing/0001213900-24-060156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.